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Abstract 
 
To investigate autoantibodies related to excitation–contraction (E-C) coupling in 
patients with myasthenia gravis (MG), we developed a novel method to detect 
autoantibodies against dihydropyridine receptor (DHPR).  Using this method, we 
detected DHPR antibody in 37% (11 out of 30) of MG patients with thymoma.  
Antibodies were not detected in normal nor disease controls.  The titer of DHPR 
antibodies showed no significant correlation with autoantibodies to acetylcholine nor 
ryanodine receptors.  The DHPR antibody is another marker for thymoma in MG, and 
it might have some role in clinical symptoms related to E-C coupling. 
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1. Introduction 
 
Myasthenia gravis (MG) is an autoimmune disease with impaired 
neuromuscular transmission mainly due to the effect of autoantibodies to acetylcholine 
receptor (AChR) (Conti-Fine et al., 2006). Recently, dysregulation of sarcoplasmic 
reticulum (SR) Ca2+ relaease has been associated with muscle fatigue (Bellinger et al., 
2008).  An electrophysiological study showed that fatigue in MG patients was caused 
not only by abnormal neuromuscular transmission but also by impairment of 
excitation-contraction (E-C) coupling (Pagala et al., 1993).  In the process of E-C 
coupling in skeletal muscle, ryanodine receptor (RyR) and dihydropyridine receptor 
(DHPR) function as Ca2+ channels (Takeshima et al., 1994). Autoantibody against RyR 
(RyR Ab) was previously detected from sera of MG patients with a large majority of 
them being associated with thymoma (Mygland et al., 1992; Takamori et al., 2004).  
However, RyR is intracellular protein, and evidence that RyR Abs are pathogenic in vivo 
is still missing (Skeie et al., 2006).  Therefore, a new method to detect autoantibodies 
against other E-C coupling-related proteins facing to outside of muscle cells is 
necessary to explain the pathogenesis of the E-C coupling-impairment in MG.  In this 
study, we developed a new method to detect specific autoantibodies against DHPR 
(DHPR Abs) and studied their frequency in MG patients. 
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We examined serum samples from 57 patients with MG (male: 22; female: 35, 
with thymoma: 30; without thymoma: 27, ocular: 13; generalized: 44, AChR 
Ab-positive: 48; AChR Ab-negative: 9 [1; muscle-specific kinase (MuSK) Ab-positive], 
mean of onset age; 51.9 year-old), 14 patients with Lambert-Eaton myasthenic 
syndrome (LEMS), 35 disease controls (thymoma without MG: 7, other neurological 
disorders: 28) and 20 age-matched normal subjects.  The clinical histories and 
laboratory data of patients were fully collected and reviewed by our physicians for the 
accuracy of diagnosis.  Serum samples were drawn before starts of any 
immunosuppressive therapies and stocked at –20˚C until measurement. Their titers of 
AChR Ab were measured by immunoprecipitation assay using 125I-α-bungarotoxin 
labeled AChR from TE671 (Lindstrom et al., 1976). Their titers of anti-P/Q-type 
voltage-gated calcium channel (VGCC) antibody (P/Q-VGCC Ab) were measured by 
immunoprecipitation assay using 125I-ω-conotoxin MVIIC labeled P/Q-type VGCC 
from rat cerebellum (Motomura et al., 1997).  
 
2.2 DHPR Ab and RyR Ab 
 
We used the ELISA starter accessory package (Bethyl Laboratories, 
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Montgomery, TX) to perform sandwich ELISA procedure.  The monoclonal antibody 
(mAbs) to DHPR (clone 1A, Sigma Aldrich Inc., St Louis, MI) (Morton and Froehner, 
1987) (Morton et al., 1988) and horseradish peroxidase (HRP)-conjugated anti-human 
immunoglobuline G (IgG) antibody (ICN Pharmaceuticals Inc., Aurora, OH) were 
utilized.  A crude extract of DHPRs / RyRs was obtained from the skeletal muscle of 
rabbits as previously described (Inui et al., 1987; Iwasa, 1997; Saito et al., 1984). We 
found DHPR in R2 fraction and RyR in R3 fraction by the western blotting method with 
mAbs to each protein (clones 1A and 34C respectively).  A microtiter plate was coated 
with mAbs to DHPR (2 µg/ml) or negative control included BSA for 1 hour and was 
blocked with the postcoat solution buffer (Bethyl Laboratories) for 30 minutes.  The 
plate was then incubated with the DHPR extract (R2 fraction).  After these steps, 
human sera were applied to the plates.  Then, we performed standard procedure for 
ELISA.  The optical density (OD)-values were read at 450 nm with Multiskan MS-UV 
(Labsystems, Helsinki, Finland).  The result is expressed as net OD in which the value 
of negative control, coated with BSA, was subtracted. Titers that exceeded the average 
+ 3X standard deviation of normal samples were defined as the positive.  To optimize 
assay procedure, we examined titers with various volumes of applied samples from a 
DHPR Ab-positive patient and a normal subject.  We also detected DHPR Abs 
qualitatively by the western blotting method with standard procedure using the DHPR 
extract (R2 fraction) as the antigen and sample sera or mAbs (clone 1A) to DHPRs as 
the antibodies.  Their titers of RyR Abs were measured by sandwich ELISA assay 
procedure same as for DHPR Abs, using mAbs to RyRs (clone 34C, Sigma-Aldrich Inc., 
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Antibody-positive rates were analyzed using Fisher’s exact probability test.  
The correlation of the titer of DHPR Abs and other kinds of antibodies was elucidated 
using Spearman’s rank correlation test. 
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3. Result 
 
Of 30 patients of MG with thymoma (T-MG), 11 patients (37%) were positive 
for DHPR Abs (Figure 1A).  On the other hand all samples from MG without 
thymoma (N-MG), disease control (DC) and normal control (NC) were negative.  The 
titers of positive sera changed depending on the volume of applied sample (Figure 1B).  
The western blotting method also detected DHPR Abs in samples that were DHPR 
Ab-positive by this procedure (Figure 1C).   
Even though we did not detect of DHPR Abs from samples without AChR Abs, 
there was no significant correlation between these two autoantibodies (Figure 2A).  
Furthermore, in spite of DHPR Abs not being detected in samples without RyR Abs, 
there was no significant correlation between these two autoantibodies (Figure 2B).  
Additionally, P/Q-VGCC Abs were not detected in samples with DHPR Abs. 
In T-MG, the positive rate for DHPR Ab was higher in female than male 
(Table). Of 11 patients of DHPR Abs-positive, only one patient was ocular type and 
others were generalized type.  However, no difference in positive rates was found in 
patients with late-onset (after 40 years of age) and in those with early-onset.  Moreover, 
there was no difference of MG onset age or MG ADL score between DHPR Ab-positive 
and -negative patients with T-MG (Figure 3A, 3B).  Concerning to the WHO 
classification of thymoma, of 11 DHPR Ab-positive patients, three had B1, four had B2, 
three had B3 and one had unknown thymoma (Figure 3C). 
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4. Discussion 
 
In this study, we developed a new measurement method to detect 
autoantibodies against DHPR. Using this method, we could detect DHPR Abs from 
37% of T-MG samples. All tested samples were drown before any immunological 
therapies. In T-MG, the positive rate of this antibody has tendencies to be high in female 
and in generalized type. All samples with DHPR Abs have also AChR and RyR Abs.  
However, the titers of these antibodies do not have significant correlation with each 
other.  Moreover, the sequence of DHPR has no significant similarity with those of 
AChR (Noda et al., 1983) or RyR (Tanabe et al., 1987; Zorzato et al., 1990). On the 
other hand, there was no sample that was positive for both DHPR Ab and P/Q-VGCC 
Abs, in spite of several significant similar regions between these two types of VGCC 
(Perez-Reyes et al., 1992; Tanabe et al., 1987) 
So far, DHPR Abs have not been measured in MG sera.  However, there were 
several methods for the detection of autoantibodies to AChRs from sera with MG 
(Lindstrom et al., 1976). The immunoprecipitation assay could detect antibodies to the 
complex of AChR and α-bungarotoxin, which is a specific ligand to AChR.  After that, 
the ELISA method using anti-AChR mAbs was designed without utilization of the 
neurotoxin and radio-isotope (Dwyer et al., 1983). Using this ELISA method, with some 
modification, we could detect disease specific Abs from T-MG sera in this study, with a 
specificity of 100% and a sensitivity of 37%.  Since the mAbs (clone 1A) bound to 
DHPRs specifically (Morton et al., 1988), the Abs we detected in patients sera was 
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thought to have specificity to DHPR.  There was no correlation between the titers of 
DHPR Abs and other antibodies detected from MG or LEMS sera in our study.  These 
results suggest that DHPR Abs could be produced independently in the patients with 
T-MG. However, if only the DHPR Ab-positive patients are taken, there is correlation 
with RyR Ab titers (p<0.05).  There might be two different populations in T-MG 
patients with RyR Ab. 
In general, physiological processes which lead to muscle contraction, include 
electrical (nerve conduction, neuromuscular transmission and muscle membrane 
excitation) and mechanical (E-C coupling and muscle contractility) responses (Pagala et 
al., 1993).  Fatigue in MG patients is caused by impairment of E-C coupling as well as 
abnormal neuromuscular transmission (Pagala et al., 1993). Both RyR and DHPR are 
calcium channels participated in E-C coupling of skeletal muscle (Takeshima et al., 
1994).  From some sera of patients with MG, RyR Abs could be detectable (Takamori 
et al., 2004). However, since RyR is intracellular protein, the evidence that RyR Abs are 
pathogenic in vivo is still missing (Skeie et al., 2006). On the other hand, since DHPR is 
a membrane protein facing to outside of cytoplasm,(Grabner et al., 1998) DHPR Abs 
that we noted here could easily access targets and be pathogenic for the impairment of 
E-C coupling.  Our method is useful to detect antibodies against DHPRs and would 
contribute to clarification of the roles of antibodies in another pathogenesis of MG. 
Further accumulation of patients and physiological evaluation of E-C coupling 
of these patients should be addressed. 
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Detection of DHPR Ab 
A. Titers of DHPR Ab. Titers that exceeded the average + 3 x standard deviation of 
normal samples (broken bar) were defined as the positive.  Eleven out of 30 patients 
(37%) with T-MG were positive for DHPR Ab.  On the other hand, all of N-MG, 
LEMS, DC and NC were negative.  
B. Titers with various volumes of applied samples. OD values of MG sample with 
DHPR Ab increased depending on the applied volume.  On the other hand, OD values 
of NC sample did not increase in spite of the change of the applied volume. 
C. DHPR Ab detected with the western blotting method 
Western blotting method also could detect DHPR Ab from DHPR Ab positive samples 
by our method [lane 2] and did not detect DHPR Ab from NC samples [lane 3].  Lane 
1; anti-DHPR monoclonal antibody (arrow head), Lane 2; sample of DHPR Ab positive 
by our method, Lane 3; NC sample. 
 
DC; disease control, DHPR; dihydropyridine receptor, DHPR Ab; autoantibody to 
DHPR, LEMS; Lambert-Eaton myasthenic syndrome, MG; myasthenia gravis, NC; 
normal control, N-MG; MG with normal thymus, T-MG; MG with thymoma 
 
Figure 2.  
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Correlation between titers of DHPR Ab and other autoantibodies.  
A. DHPR Ab and AChR Ab. There was no correlation between titers of DHPR-Ab and 
AChR-Ab (n=35, ρs=0.24). 
B. DHPR Ab and RyR Ab. There was not so significant correlation between titers of 
DHPR Ab and RyR Ab (n=57, ρs=0.40).  
AChR Ab; autoantibody to acetylcholine receptor, DHPR Ab; autoantibody to 
dihydropyridine receptor, DHPR Ab (+); DHPR Ab positive, DHPR Ab (-); DHPR Ab 
negative, MG; myasthenia gravis, RyR Ab; autoantibody to ryanodine receptor. 
 
Figure 3. 
DHPR Ab and clinical features of MG patients. 
A. Onset age of MG in patients with and without DHPR Ab. There was no difference of 
MG onset ages between DHPR Ab-positive and -negative patients with T-MG.  
B. MG ADL score in patients with and without DHPR Ab.  There is no difference of 
MG ADL score between DHPR Ab-positive and -negative patients with T-MG. 
C. DHPR Ab and thymoma types.  Of 11 DHPR Ab-positive patients, three had B1, 
four had B2, three had B3 and one had unknown types by the WHO classification of 
thymoma.  

















































































































































T-MG without DHPR Ab (n=20)
*; p<0.01, analyzed with N-MG, LEMS, DC or NC.    
Lambert-Eaton myasthenic syndrome (LEMS, n=14)
Myasthenia gravis without thymoma (N-MG, n=27)
T-MG with DHPR Ab (n=10)
] n.s.General type T-MG (n=23)
Table. Positive rate of DHPR Ab and RyR Ab
DHPR Ab RyR Ab
Positive rate
] n.s.] n.s.Female patients with T-MG (n=18)Male patients with T-MG (n=12)
T-MG without RyR-Ab (n=9) ] p<0.01
T-MG with RyR-Ab (n=21)
Myasthenia gravis with thymoma (T-MG, n=30)
DHPR-Ab; anti-dihydropyridine receptor antibody.
RyR-Ab; anti-ryanodine receptor antibody.
Disease Control (DC, n=35)
Normal Control (NC, n=20)
Fisher's exact probability test was used for analysis.
(n.s.; no significnt difference)
AChR-Ab; anti-acetylcholine receptor antibody.
Ocular type T-MG (n=7) ] n.s.
p<0.01
p<0.01
